The Importance of Being Seen and Heard In April 2021, Paula Ngon was an active, young public relations professional living in New York City, navigating life amid a global pandemic. One day, not feeling well and concerned about swollen lymph…
Updates from the 2022 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 300 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific…
ASH 2022: High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Plus Venetoclax Investigators reported updated results from a phase II trial exploring the use of ibrutinib-venetoclax combination therapy in patients with high-risk…
ASH 2022: Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy Consolidation with either whole-brain radiation therapy (WBRT) or autologous stem cell transplant (autoSCT) improves overall survival in patients with primary central nervous system lymphoma (PCNSL), regardless of first-line…
ASH 2022: Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Combination therapy with rituximab (Rituxan) and lenalidomide (Revlimid) was approved for use in relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) based on the results…
ASH 2022: Updated Index Improves Prognostication for Survival in Advanced-Stage Hodgkin Lymphoma Models that have historically been used to predict survival outcomes in advanced-stage classical Hodgkin lymphoma (A-HL) are outdated and less useful in the modern treatment era. Members of…
ASH 2022: Next-Generation BTKi Zanubrutinib Demonstrates Improved Efficacy and Tolerability Compared with Ibrutinib The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib (Imbruvica) has become the standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) but can cause…
ASH 2022: Durable Responses Observed with Mosunetuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma In research presented by Nancy Bartlett, MD, a past Scientific Advisory Board (SAB) member and LRF grantee, durable clinical responses were observed in patients with relapsed/refractory follicular lymphoma…
ASH 2022: Quality of Life Improves Quickly in Survivors of Aggressive Lymphomas Lymphomas are a potentially curable subset of cancers, but long-term treatment or disease effects may impact quality of life. Researchers, therefore, sought to determine how quality of life…
ASH 2022: Short-course Brentuximab Vedotin with Chemotherapy is Highly Active in Early-Stage Bulky Hodgkin LymphomaASH 2022 Treatment with short-course brentuximab vedotin (Adcetris; BV), an antibody-drug conjugate, combined with chemotherapy in early-stage, bulky Hodgkin lymphoma (HL) was associated with four-year overall…